Precocious Puberty

Treat breast development before age 8 years in girls or testicular enlargement before age 9 years in boys as possible central precocious puberty (CPP), particularly when physical changes follow the usual isosexual pubertal sequence with accelerated linear growth and advancing skeletal maturation. CPP reflects premature hypothalamic-pituitary-gonadal activation and can advance bone age sufficiently to reduce adult-height potential. accessdata fda+2accessdata fda[PDF] 020263Orig1s042 | FDAThe LancetCentral precocious puberty: a review of diagnosis, treatment, and outcomesendocrineENP113: Clinical Practice Guideline on Central Precocious Puberty | Endocrine Society

For a girl presenting with Tanner B2 breast development at age 7.0-8.0 years, perform serial physical examinations rather than immediate hormonal testing or imaging. Confirm palpable glandular tissue rather than adipose tissue in patients with overweight or obesity. A 4-6-month observation period is also appropriate for initial B2 development before age 7 years when the presentation is not clearly rapidly progressive; progression during surveillance changes the next step to diagnostic evaluation. endocrine+1endocrineCentral Precocious Puberty - Endocrine Societyendocrinenews endocrineThey Grow Up So Fast: Endocrine Society Releases Central Precocious Puberty Guideline - Endocrine News

Move directly from observation to evaluation when development is rapidly progressive, when growth acceleration or skeletal maturation is evident, or when findings are discordant with ordinary central puberty. Boys with sexual precocity merit careful etiologic assessment because underlying disorders are more frequent than in girls. ScienceDirect+1ScienceDirectPremature AdrenarcheScienceDirectPrecocious Puberty - an overview

Use a GnRH or GnRH-agonist stimulation test when the clinical question is whether early findings represent CPP. A stimulated LH greater than 5 IU/L is a commonly used discriminator for central activation. In boys, basal LH greater than 0.3 IU/L and stimulated LH greater than 5 IU/L are distinctive; these measures perform less reliably in girls, especially at Tanner stages 2-3. PubMedPubMedGonadotropin-releasing hormone stimulation test and diagnostic cutoff in precocious puberty: a mini review - PMC

Use basal LH as a screening test, not as a replacement for stimulation testing in girls with equivocal early findings. Although basal LH greater than 1.0 IU/L has reported positive predictive value of 96.4% for CPP, a basal threshold above 1.1 IU/L has limited sensitivity and specificity and should not independently exclude CPP. PubMedPubMedGonadotropin-releasing hormone stimulation test and diagnostic cutoff in precocious puberty: a mini review - PMC

Do not use FSH concentration alone to distinguish CPP from early puberty in girls age 7-8 years because basal and stimulated FSH are nonconclusive. When gonadotropin responses remain low in an early-pubertal girl, correlate with clinical progression; an estradiol peak up to 50 pg/mL measured 20-24 hours after leuprolide stimulation may help identify CPP. PubMedPubMedGonadotropin-releasing hormone stimulation test and diagnostic cutoff in precocious puberty: a mini review - PMC

CPP can be idiopathic, especially in girls, but may also reflect cerebral congenital malformations or acquired central nervous system insults. Once CPP is established, use the patient’s sex, age, neurologic history, tempo, and examination findings to determine the urgency and scope of central nervous system assessment. Brain imaging is part of the evaluation framework for true precocious puberty, whereas isolated benign variants do not automatically require the same workup. ScienceDirect+1ScienceDirectPremature Thelarche: Age at Presentation Affects Clinical Course but Not Clinical Characteristics or Risk to Progress to Precocious PubertyScienceDirectPrecocious Puberty - an overview

Peripheral precocious puberty is gonadotropin-independent and should be managed according to its cause rather than with CPP suppression alone. Consider hormone-secreting tumors when secondary sexual characteristics develop without central-axis activation; evaluate virilizing androgen excess for adrenal steroidogenic defects, including late-onset 21-hydroxylase deficiency, and adrenal tumors. ScienceDirect+2ScienceDirectPremature AdrenarcheScienceDirectPrecocious Puberty - an overviewelearning rcog org ukUnderstanding precocious puberty in girls - Ovid

Do not label isolated breast development as CPP unless progression establishes broader pubertal activation. Premature thelarche lacks accelerated linear growth, rapid breast progression, and advanced skeletal maturation; it commonly presents in toddlers and may regress after several months. ScienceDirectScienceDirectPremature Thelarche: Age at Presentation Affects Clinical Course but Not Clinical Characteristics or Risk to Progress to Precocious Puberty

GnRH agonists are indicated for pediatric patients with CPP and are used to suppress pituitary gonadotropins and peripheral sex steroids. The treatment objective is to arrest progressive pubertal advancement and mitigate accelerated bone maturation that can diminish adult height. The decision is individualized; older girls with slowly progressive puberty may not require the same testing or treatment intensity as younger or rapidly progressive patients. accessdata fda+3accessdata fda[PDF] 020263Orig1s042 | FDAaccessdata fda[PDF] HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights ...endocrineCentral Precocious Puberty - Endocrine SocietyendocrineNot all children with early puberty need the same level of testing or treatment | Endocrine Society

Leuprolide depot-ped is administered intramuscularly by a health care professional. Available regimens include weight-based monthly starting doses of 7.5 mg, 11.25 mg, or 15 mg; 11.25 mg or 30 mg every 3 months; and 45 mg every 6 months. Do not use partial syringes or combine syringes because formulations have different release characteristics. If pituitary gonadotropins and peripheral sex steroids remain inadequately suppressed at the maximal dose, consider another available GnRH agonist indicated for CPP. accessdata fdaaccessdata fda[PDF] HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights ...

Triptorelin extended-release suspension is an alternative for patients age 2 years or older: administer 22.5 mg intramuscularly once every 24 weeks, by a health care provider. Discontinue at an age judged appropriate for physiologic pubertal onset; routine continuation beyond chronological age 10.0-11.0 years in girls or 11.0-12.0 years in boys, and/or bone age 11.0-12.0 years in girls or 12.0-13.0 years in boys, is discouraged. accessdata fda+1accessdata fda[PDF] This label may not be the latest approved by FDA. For current ...endocrineCentral Precocious Puberty - Endocrine Society

Monitor GnRH-agonist response with clinical pubertal progression, growth rate, and hormonal suppression. For triptorelin, assess LH after a GnRH or GnRH-agonist stimulation test, basal LH, or serum sex-steroid concentrations beginning 1-2 months after initiation, thereafter as needed to confirm efficacy, and with each subsequent dose; measure height to calculate growth rate. accessdata fdaaccessdata fda[PDF] This label may not be the latest approved by FDA. For current ...

For leuprolide, monitor hormonal and clinical parameters to ensure adequate suppression. If suppression remains inadequate despite maximal dosing, reassess adherence and dosing formulation, confirm the biochemical pattern, and consider switching to another GnRH agonist approved for CPP rather than combining or partially dosing depot syringes. accessdata fda+1accessdata fda[PDF] 020263Orig1s042 | FDAaccessdata fda[PDF] HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights ...

Plan discontinuation around anticipated physiologic pubertal timing and residual growth potential. Avoid routine treatment extension beyond the guideline age and bone-age ranges, and counsel families that pubertal maturation resumes after discontinuation; median time to menarche was 1.1 years in one long-term triptorelin cohort. BMJ+1BMJFinal height in central precocious puberty after long term treatment with a slow release GnRH agonist. | Archives of Disease in ChildhoodendocrineCentral Precocious Puberty - Endocrine Society